Business Description
Northeast Pharmaceutical Group Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE0000009G0
Share Class Description:
SZSE:000597: Class ACompare
Compare
Traded in other countries / regions
000597.China IPO Date
1996-05-23Description
Northeast Pharmaceutical Group Co Ltd is engaged in the production and distribution of ammonium phosphate, sulfuric acid, cement, compound fertilizer, bromine, raw salt, and diammonium phosphate.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.55 | |||||
| Equity-to-Asset | 0.33 | |||||
| Debt-to-Equity | 0.45 | |||||
| Debt-to-EBITDA | 3.92 | |||||
| Interest Coverage | 8.25 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 1.17 | |||||
| Beneish M-Score | -2.66 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -1.6 | |||||
| 3-Year EBITDA Growth Rate | 12 | |||||
| 3-Year EPS without NRI Growth Rate | 162.1 | |||||
| 3-Year FCF Growth Rate | 20.8 | |||||
| 3-Year Book Growth Rate | 5.8 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 68.35 | |||||
| 9-Day RSI | 58.65 | |||||
| 14-Day RSI | 55.28 | |||||
| 6-1 Month Momentum % | -4.23 | |||||
| 12-1 Month Momentum % | -14.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.02 | |||||
| Quick Ratio | 0.88 | |||||
| Cash Ratio | 0.59 | |||||
| Days Inventory | 97.93 | |||||
| Days Sales Outstanding | 91.88 | |||||
| Days Payable | 358.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.11 | |||||
| Dividend Payout Ratio | 0.28 | |||||
| Forward Dividend Yield % | 2.11 | |||||
| 5-Year Yield-on-Cost % | 2.11 | |||||
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | 15.64 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 40.68 | |||||
| Operating Margin % | 7.84 | |||||
| Net Margin % | 4.35 | |||||
| FCF Margin % | 4.26 | |||||
| ROE % | 7.57 | |||||
| ROA % | 2.5 | |||||
| ROIC % | 6.36 | |||||
| ROC (Joel Greenblatt) % | 12.18 | |||||
| ROCE % | 10.07 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 19.28 | |||||
| PE Ratio without NRI | 13.58 | |||||
| Shiller PE Ratio | 68.86 | |||||
| Price-to-Owner-Earnings | 52.4 | |||||
| PEG Ratio | 1.46 | |||||
| PS Ratio | 0.83 | |||||
| PB Ratio | 1.38 | |||||
| Price-to-Tangible-Book | 1.66 | |||||
| Price-to-Free-Cash-Flow | 19.62 | |||||
| Price-to-Operating-Cash-Flow | 11.8 | |||||
| EV-to-EBIT | 5.87 | |||||
| EV-to-EBITDA | 5.87 | |||||
| EV-to-Revenue | 0.4 | |||||
| EV-to-FCF | 9.1 | |||||
| Price-to-Projected-FCF | 1.09 | |||||
| Price-to-Median-PS-Value | 0.96 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.29 | |||||
| Price-to-Graham-Number | 1 | |||||
| Earnings Yield (Greenblatt) % | 17.04 | |||||
| FCF Yield % | 5.1 | |||||
| Forward Rate of Return (Yacktman) % | 16.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Northeast Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 8,243.175 | ||
| EPS (TTM) (Â¥) | 0.25 | ||
| Beta | 0.79 | ||
| Volatility % | 22.93 | ||
| 14-Day RSI | 55.28 | ||
| 14-Day ATR (Â¥) | 0.14082 | ||
| 20-Day SMA (Â¥) | 4.727 | ||
| 12-1 Month Momentum % | -14.7 | ||
| 52-Week Range (Â¥) | 3.77 - 6 | ||
| Shares Outstanding (Mil) | 1,429.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Northeast Pharmaceutical Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Northeast Pharmaceutical Group Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Northeast Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Northeast Pharmaceutical Group Co Ltd(SZSE:000597)'s stock price today?
The current price of SZSE:000597 is ¥4.82. The 52 week high of SZSE:000597 is ¥6.00 and 52 week low is ¥3.77.
When is next earnings date of Northeast Pharmaceutical Group Co Ltd(SZSE:000597)?
The next earnings date of Northeast Pharmaceutical Group Co Ltd(SZSE:000597) is .
Does Northeast Pharmaceutical Group Co Ltd(SZSE:000597) pay dividends? If so, how much?
The Dividend Yield %  of Northeast Pharmaceutical Group Co Ltd(SZSE:000597) is 2.11% (As of Today), Highest Dividend Payout Ratio of Northeast Pharmaceutical Group Co Ltd(SZSE:000597) was 0.56. The lowest was 0.18. And the median was 0.2. The  Forward Dividend Yield % of Northeast Pharmaceutical Group Co Ltd(SZSE:000597) is 2.11%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers